This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Steele, P. Articles by Genton, E. Search for Related Content PubMed PubMed Citation Articles by Steele, P. Articles by Genton, E.

Circulation, Vol 52, 473-476, Copyright © 1975 by American Heart Association

ARTICLES

Effects of clofibrate and sulfinpyrazone on platelet survival time in coronary artery disease

P Steele, D Battock and E Genton

Platelet survival time was measured (autologous labelling with 51chromium) in 68 men with coronary artery disease (CAD). Survival was shortened slightly (3.2 +/- 0.04 days; mean +/- SEM) as compared to normal (3.7 +/- 0.04 days; N = 18; P less than 0.001), and 60% had shortened survival (less than 3.3 days). Thirty-seven had hyperlipoproteinemia (36 with Type IV and one with Type III) and platelet survival was shortened (3.1 +/- 0.10 days) and significantly different from survival of men with normal lipoproteins (3.3 +/- 0,12 days; P less than 0.05). Twenty-two with shortened platelet survival and CAD received either clofibrate or sulfinpyrazone. Clofibrate prolonged platelet survival (2.6 +/- 0.09 to 3.4 +/- 0,14 days; P less than 0.001) and ten of 12 had prolongation of survival. Sulfinpyrazone increased survival (2.8 +/- 0.12 to 3.6 +/- 0.21; P less than 0.001) and nine of ten had prolognation of platelet survival. Clofibrate lowered serum cholesterol and tryglyceride but alteration in lipids did not correlate with alteration of survival. Sulfinpyrazone did not alter lipids. Data suggest that survival is shortened in CAD and that clofibrate and sulfinpyrazone alter survival. Platelet suppressant agents may prove beneficial in reducing the extent and complications of atherosclerotic arterial injury.

This article has been cited by other articles:

				W. C. Krupski and J. H. Rapp Smoking and Atherosclerosis Perspectives in Vascular Surgery and Endovascular Therapy, January 1, 1988; 1(1): 103 - 134. [PDF]

				A. duP. Heyns, M. G. Lotter, P. N. Badenhorst, H. Pieters, C. J. C. Nel, and P. C. Minnaar Kinetics and Fate of Indium 111 Oxine-Labeled Platelets in Patients With Aortic Aneurysms Arch Surg, September 1, 1982; 117(9): 1170 - 1174. [Abstract] [PDF]

				B. G. Brown Coronary Vasospasm: Observations Linking the Clinical Spectrum of Ischemic Heart Disease to the Dynamic Pathology of Coronary Atherosclerosis Arch Intern Med, May 1, 1981; 141(6): 716 - 722. [Abstract] [PDF]